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1  | INTRODUC TION
Lumpfish (Cyclopterus lumpus L.), also known as lumpsucker, are now 
farmed and used as cleaner fish to remove sea lice from farmed 
Atlantic salmon in Europe and Canada (Powell et al., 2018; Treasurer, 
2018; Haugland et al., 2020). In Norway, the number of farmed lump-
fish has increased rapidly in recent years and 34 million lumpfish 
were deployed in 2020 (http://www.fiske ridir.no). High mortality 
among lumpfish has been reported, most caused by bacterial infec-
tions with atypical Aeromonas salmonicida, Vibrio spp., Pasteurella sp. 
or Pseudomonas anguilliseptica (Scholz et al., 2018; Erkinharju, Dalmo, 
et al., 2021; Erkinharju, Grønbech et al., 2021). The Pasteurella sp. 
isolates from lumpfish have recently been named Pasteurella atlan-
tica (Ellul et al., 2021; Erkinharju, Grønbech et al., 2021). Atypical and 
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Abstract
Lumpfish is a novel farmed species used as cleaner fish for the removal of lice from 
farmed salmon. As often with new, farmed species, there are challenges with bac-
terial infections. The frequency of prescription of antibiotic agents to lumpfish is 
increasing, despite the lack of knowledge about appropriate doses, duration of treat-
ment and application protocols for the various antibacterial agents. In the current 
study, we have tested the effect of medicated feed with florfenicol (FFC), oxolinic 
acid (OA) and flumequine (FLU) on lumpfish experimentally challenged with Vibrio 
anguillarum, atypical Aeromonas salmonicida and Pasteurella atlantica. We found that 
all three antibacterial agents efficiently treated lumpfish with vibriosis using 10 and 
20 mg kg−1 day−1 of FFC, 25 mg kg−1 day−1 of OA and 25 mg kg−1 day−1 FLU, whereas 
only FFC (20 mg kg−1 day−1) had good effect on lumpfish with pasteurellosis. None 
of the antibacterial agents were efficient to treat lumpfish with atypical furunculosis. 
FFC 20 mg kg−1 day−1 showed promising results in the beginning of the experiment, 
but the mortality increased rapidly 14 days post- medication. Efficient treatment is 
important for the welfare of lumpfish and for reducing the risk of development of 
antibiotic- resistant bacteria. To our knowledge, this is the first study to establish pro-
tocols for antibacterial treatment of lumpfish.
K E Y W O R D S
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typical A. salmonicida, major pathogens of diverse fish species found 
in both marine and freshwater environments (reviewed in Wiklund & 
Dalsgaard, 1998; Menanteau- Ledouble et al., 2016), can be divided 
into 14 subgroups, based on variation in the gene (vapA) encoding 
the A- layer protein (Gulla et al., 2016). A. salmonicida is a highly di-
verse group of bacteria, both regards to biochemical characteristics, 
growth conditions and extracellular proteases, and includes several 
atypical strains. Pathogenic bacteria for lumpfish are dominated by 
atypical A. salmonicida isolates belonging to A- layer group VI. Among 
Vibrio spp., V. anguillarum is the major pathogen, but other Vibrio 
species have also caused mortality, including V. ordalii, V. tapetis, 
V. logei, V. wodanis and V. splendidus (Erkinharju, Dalmo, et al., 2021; 
Erkinharju, Grønbech et al., 2021; Haugland et al., 2020). Except for 
V. ordalii, it is debated whether these are primary or secondary patho-
gens. Furthermore, P. atlantica causing systemic bacterial infection in 
lumpfish has become a serious infection problem (Alarcon et al., 2016; 
Ellul, Walde, et al., 2019; Ellul et al., 2021). Phenotypically and histo-
pathologically, the P. atlantica isolates from lumpfish are similar, but 
not identical, to Pasteurella spp. isolated from farmed Atlantic salmon 
in Norway and Pasteurella skyensis in Scotland (Alarcon et al., 2016; 
Ellul, Walde, et al., 2019; Ellul et al., 2021).
Efforts to develop vaccines to protect against bacterial diseases 
in lumpfish are ongoing (Rønneseth, Brudal, et al., 2017; Rønneseth, 
Haugland, et al., 2017; reviewed in Haugland et al., 2018; Haugland & 
Rønneseth, 2018, Ellul, Walde, et al., 2019, Chakraborty et al., 2019; 
Erkinharju et al., 2017; 2018; 2019). In Norway, lumpfish are vac-
cinated by intraperitoneal (i.p.) injection against vibriosis and atyp-
ical furunculosis when they have reached a minimum size of 8 g 
(Haugland et al., 2018). The vaccines protect against vibriosis, but 
atypical furunculosis is still a problem in farmed lumpfish. Atypical 
A. salmonicida is a heterogenic group, and it is difficult to identify one 
isolate that protects against all subtypes (Nordstrand et al., 2017). 
The vaccines currently available do not include P. atlantica, one 
of the major reasons being the fastidious growth requirements of 
this bacterium. Recently, Ellul, Walde, et al. (2019) and Ellul, Bulla, 
et al. (2019) were able to cultivate P. atlantica in broth media to a 
density of 2 × 109 bacteria ml−1 and establish a bath challenge model 
(Ellul, Walde, et al., 2019). Two R&D vaccines against pasteurellosis 
have been tested, but despite high levels of specific antibodies being 
raised, the vaccines did not provide sufficient protection against 
disease (Ellul, Bulla, et al., 2019). At early life stages (<8 g), immer-
sion vaccination can be performed, but it is not yet known at what 
size/age the lumpfish is immunocompetent (Rønneseth, Haugland, 
et al., 2017; Chakraborty et al., 2019). As bacterial diseases affect 
lumpfish in all stages of the production, treatment by antibacterial 
agents is often the only option for juvenile fish. Lumpfish in sea pens 
with salmon are not treated with antibacterial agents, and develop-
ment of efficient vaccines is therefore crucial.
Despite progress in development of immune prophylactic measures 
to lumpfish (Haugland et al., 2018; Ellul, Bulla, et al., 2019), the number 
of treatments with antibacterial agents is still high (Grave et al., 2019). 
Excessive or improper use of antibacterials may lead to development 
of resistance in bacterial pathogens. In recent years, there has been 
an increased understanding of the mechanisms of antimicrobial resis-
tance (Miranda, Tello et al., 2013; Blair, Webber et al., 2015; Munita & 
Arias, 2016) and the use of antibiotics in aquaculture is a worldwide 
concern. Antibacterials currently authorized for use in salmon aqua-
culture vary between countries, where oxytetracycline, florfenicol 
(FFC), trimethoprim/sulpha derivatives and quinolones are among the 
most widely used substances (Cabello et al., 2013). Oxolinic acid (OA) 
and florfenicol have shown high efficacy in treating several bacterial 
diseases in Atlantic halibut (Hippoglossus hippoglossus L.), corkwing 
wrasse (Symphodus melops L.), Goldsinny wrasse (Ctenolabrus rupes-
tris L.), turbot (Scophthalmus maximus L.), Atlantic cod (Gadus morhua 
L.) and Atlantic salmon (Salmo salar L.) (Samuelsen, 1997; Samuelsen 
et al., 1998; Samuelsen et al., 1999; Samuelsen et al., 2000; Samuelsen 
et al., 2002; Samuelsen, 2003; Samuelsen et al., 2003). In Norway, 
medicated feeds containing FFC (0.83 and 2 g FFC per kg feed) and OA 
(5 g OA per kg feed) are commercially available for lumpfish. However, 
efficacy studies have not yet been reported. Prior to initiating treat-
ment of diseased fish, it is important to know the sensitivity of the 
pathogen for the antibacterial agent considered for use. Knowledge of 
the sensitivity and minimum inhibitory concentration (MIC) value can, 
together with pharmacokinetic data, be used to calculate a theoret-
ical concentration of an antibacterial needed to achieve an effective 
treatment (Kverme et al., 2019; Haugland et al., 2019). It is, however, 
of major importance that the efficacy of antibacterial treatments is ex-
perimentally verified. Kverme et al. (2019) uncovered some isolates of 
A. salmonicida with reduced sensitivity towards OA, but high sensitiv-
ity to flumequine (FLU). Furthermore, Haugland et al. (2019) showed 
that FLU has advantageous pharmacokinetic properties in lumpfish 
compared with OA. Thus, the current study was initiated to evaluate 
the efficacy of FFC, OA and FLU in treating experimentally induced 
infections with V. anguillarum, atypical A. salmonicida and P. atlantica 
in lumpfish.
2  | MATERIAL S AND METHODS
2.1 | Experimental fish
Unvaccinated, farmed lumpfish (C. lumpus) were supplied by Vest 
Aqua Base AS, a commercial breeder in Vestland County, Norway. 
Head kidney samples from 15 to 20 fish were screened for V. anguil-
larum O1, V. anguillarum O2, atypical A. salmonicida and Pasteurella 
sp. at PHARMAQ Analytiq (a diagnostic laboratory) by real- time RT- 
PCR. All samples were negative. The fish were kept in tanks (500 
L) at the Aquatic and Industrial Laboratory (ILAB), Bergen, Norway. 
The water temperature was 12°C, the salinity 34 ‰ and the light 
regime 12 h light: 12 h dark. The water flow was 300– 400 L per 
hours per tank, and the outlet water had a minimum of 77% oxy-
gen saturation. The fish were fed with the commercial dry feed 
Gemma Silk (Experiment 1 and Experiment 2) and Clean Assist 
(Experiment 3), 1.2- to 1.5- mm pellets (both feeds from Skretting). 
When the fish were transferred to the challenge unit at ILAB, they 
were 36.2 ± 10.6 g and 8.5 ± 0.7 cm. The animal experiments were 
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approved by the Norwegian Animal Research Authority under the 
identification codes FOTS- ID: 10178 and 14129. Permissions to 
use OA and to use and make feed with FLU were approved by the 
Norwegian Medicines Agency.
2.2 | Medical feed
Both the FFC and OA medicated feeds, Gemma Silk, 1.5- mm pellets 
(Experiment 1 and Experiment 2), and Clean Assist feed, 1.5- mm pel-
lets (Experiment 3), were commercial feeds for lumpfish (Skretting). 
The medicated feed containing FLU was made in the laboratory 
by coating the 1.5- mm pellets (Gemma Silk in Experiment 1 and 
Experiment 2, and Clean Assist in Experiment 3) with a premix of D- 
glucose and FLU as described previously (Haugland et al., 2019). Fish 
in the control group (infected, non- treated group) got regular, non- 
medicated feed (same pellet size and brand as the treated groups).
2.3 | Bacteria grown for experimental challenge
Vibrio anguillarum serotype O1 isolated from diseased lumpfish was 
cultured in tryptic soy broth (TSB) (Becton, Dickinson and Company) 
supplemented with 1.5% NaCl at 20°C, 200 rpm to late exponential 
phase. The bacteria were washed once with PBS (BioWhittaker) and 
diluted to 2 × 103 cells ml−1 using a CASY cell counter (Innovatis). 
Atypical A. salmonicida isolated from diseased lumpfish was grown in 
TSB at 18°C, 200 rpm to late exponential phase. The bacteria were 
washed once with PBS, and the bacteria number was determined by 
CASY cell counter and diluted to 1 × 105, 2 × 104 and 4 × 103 cells 
ml−1. The P. atlantica isolated from diseased lumpfish was grown in 
TBS supplemented with 1.5% NaCl and 10% foetal bovine serum 
(FBS, Australian origin; Gibco Life Technologies) as described previ-
ously (Ellul, Walde, et al., 2019). The bacteria were washed once with 
PBS, counted and diluted as described for atypical A. salmonicida.
2.4 | Bacteria grown for sensitivity testing and MIC 
determination
Vibrio anguillarum and atypical A. salmonicida were grown to late ex-
ponential phase in Mueller Hinton Broth 2 (MHB2), cation- adjusted 
(Sigma- Aldrich). P. atlantica was grown in MHB2 supplemented with 
10% FCS. All bacteria were grown at 22°C, 200 rpm. The bacteria 
were diluted to 5 × 106 bacteria ml−1, and 100 μl was added to each 
well in 96- well round- bottom microtest plates (Sarstedt). FFC, FLU 
and OA (512– 0.001 μg/ml) were included (twofold dilutions, three 
parallels of all dilutions). Controls with only bacteria, no antibiotics 
and growth medium only were included on each plate. The plates 
with V. anguillarum were incubated at 22°C for 24 h, while plates 
with atypical A. salmonicida and P. atlantica were incubated for 48 h. 
The MIC was determined after visual inspection, given as the con-
centration where no growth could be observed.
2.5 | Determination of challenge dose
Fifty μl/fish of the three doses (5 × 103, 1 × 103 and 2 × 102 bac-
teria) of atypical A. salmonicida (n = 16 per group) and P. atlantica 
(n = 20 per group) was given by i.p. injection to separate groups of 
fish. Based on cumulative mortality and time of onset of mortality 
for each dose of pathogen (Figure 1a), the most appropriate chal-
lenge doses and time point to start medication after challenge were 
determined. Initially, a dose of 1 × 102 bacteria ml−1 of V. anguillarum 
was used (n = 20 fish per tank in two tanks), based on previous ex-
periments (Rønneseth et al., 2014). However, using this dose, the 
mortality started after 5 days and the cumulative mortality reached 
only 40% (Figure 1a), which was considered low for a control group. 
Therefore, in the main experiment, the concentration of V. anguil-
larum in the suspension was increased from 1 × 102 bacteria to 
2 × 102 bacteria and the medication started 2 days post- challenge 
F I G U R E  1   Mortality curves of lumpfish following the bacterial 
challenge. (a) Cumulative mortality of lumpfish after challenge 
with 1 × 102 Vibrio anguillarum per fish. (b) Cumulative mortality 
of lumpfish after challenge with 5 × 103, 1 × 103 and 2 × 103 
atypical Aeromonas salmonicida per fish. (c) Cumulative mortality of 
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(dpc). Based on the preliminary results, a dose of 2 × 102 bacteria per 
fish and medication starting 5 dpc were chosen for atypical A. salmo-
nicida (Figure 1b). For P. atlantica, a dose of 5 × 102 bacteria per fish 
and starting medication 5 dpc were decided (Figure 1c).
2.6 | Experimental challenge and 
treatment experiment
For each of the experiments 1, 2 and 3 (see below), four hundred 
and eighty fish were transferred to the challenge rearing unit one 
week prior to challenge for acclimatization. The fish were randomly 
divided into sixteen groups of 30 fish per 150- L tanks: three parallel 
tanks for each of the four treatment regimens (Tables 1 and 2) and 
four tanks containing infected, non- treated control fish. The water 
had a temperature of 12°C, salinity of 34 ‰ and a flow rate of 6 L 
min−1. The light regime was 12 h light:12 h dark.
Experiment 1 (V. anguillarum)
The fish were challenged i.p. with 50 μl V. anguillarum bacterial sus-
pension (2 × 102 bacteria) and the medication started 2 dpc.
Experiment 2 (atypical A. salmonicida)
The fish were challenged i.p. with 50 μl atypical A. salmonicida 
(2 × 102 bacteria), and the medication started 5 dpc.
Experiment 3 (P. atlantica)
The fish were challenged i.p. with 50 μl P. atlantica. (5 × 102 bac-
teria), and the medication started 5 dpc. The antibacterial agents 
and doses administered for each experiment are listed in Table 1 
for experiments 1 and 2 and in Table 2 for Experiment 3. It has 
been speculated that P. atlantica might be a facultative intracellu-
lar bacterium (Ellul, Walde, et al., 2019). Therefore, based on previ-
ous experience with treating Fransicella noatunensis infection in cod 
(Samuelsen, unpublished results), the doses and treatment chosen 
in Experiment 3 differed from those used in experiments 1 and 2. In 
addition to medicated feed, the fish were given non- medicated feed 
in all three experiments to maintain a total daily feeding rate of 1.5% 
of the body weight.
Each morning, the fish tanks were cleaned, and a strainer was 
placed over the drain grate allowing excess feed to be collected. 
The excess feed from each tank was dried at 90°C for 18 h and the 
amount of feed consumed calculated using the factor of 1.1, that is 
the ratio of dried versus non- dried feed (Kverme, 2017).
2.7 | Macroscopic examination and 
bacteria sampling
Tissues and skin of moribund fish from all experiments were exam-
ined macroscopically. From dead and moribund fish, bacteria were 
isolated from blood, head kidney, spleen, liver and heart using a graft 
needle, and streaked onto agar plates. Samples from fish challenged 
with V. anguillarum were plated onto TSA plates with 2% NaCl and 
plates with Vibrio- specific medium containing thiosulphate– citrate– 
bile salts– sucrose agars (Sigma). Samples from fish challenged with 
atypical A. salmonicida were plated onto TSA plates. Single colonies 
were further streaked onto blue agar plates (TBS containing 0.01% 
Coomassie Brilliant Blue R- 250) to examine whether reisolated 
atypical A. salmonicida still contained A- layer. Samples from fish 
challenged with P. atlantica were streaked onto blood agar plates 
containing 2% NaCl. The isolated bacteria were identified using 16S 
rDNA sequencing and universal primers as previously described 
(Rønneseth, Brudal, et al., 2017a). Furthermore, bacteria isolated 
from Vibrio- infected fish were analysed by an agglutination test 
(MONO- Va; Bionor Laboratories AS).







Total dose during 
treatment (mg/kg)
Amount of medical feed (% 
of body weight)a
Days of treatment 
post- infection
Floraqpharma vet. FFC10 0.83g/kg 10 100 1.0% Daily, dpc 2– 11 (V. ang)
Daily, dpc 5– 14 (atyp A. sal.)
Floraqpharma vet. FFC20 2g/kg 20 200 1.0% Daily, dpc 2– 11 (V. ang)
Daily, dpc 5– 14 (atyp A. sal.)
Oxolinic acid vet. OA25 5g/kg 25 150 0.5% Dpc 2, 3, 5, 7, 9, 11 (V. ang)
Dpc 5, 6, 8,10, 12, 14 (atyp 
A. sal.).
Flumequine UB25 5g/kg 25 150 0.5% Dpc 2, 3, 5, 7, 9, 11 (V. ang)
Dpc 5, 6, 8, 10, 12, 14 (atyp 
A. sal.).
aTotal amount of medical and non- medical feed was 1.5% of body weight.
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2.8 | Statistical analyses
Kaplan- Meier survival analyses were performed using SigmaStat 3.5 
(Systat Software Inc., Richmond, USA). Log- rank tests were used to 
evaluate the effect of medical treatment, and multiple pairwise com-
parisons were done using the Holm– Sidak method. Differences were 
considered significant if p < .05. Relative percentage survival (RPS) 
values were calculated according to Inglis et al. (1991).
3  | RESULTS
3.1 | Sensitivity to antibacterials
The sensitivity, specified as MIC values, of V. anguillarum, atypical 
A. salmonicida and P. atlantica towards FFC, OA and FLU is given in 
Table 3. V. anguillarum and atypical A. salmonicida were more sensi-
tive to OA than to FLU, while P. atlantica was more sensitive to FLU. 
Highest sensitivity towards FFC was seen in P. atlantica and lowest 
in atypical A. salmonicida.
3.2 | Challenge dose test
Prior to experiments 1, 2 and 3, preliminary studies were performed 
to determine the most appropriate doses to use for challenge and 
time to start the medication. The dose of V. anguillarum gave onset 
of mortality at day 5 and a cumulative mortality of 40% (Figure 1a), 
which were in the lower region for a control group in an effective 
study. The dose for the final experiment was therefore increased 
from 1 × 102 to 2 × 102 bacteria per fish. It was decided to start the 
medication 2 dpc.
For atypical A. salmonicida, mortality started at 9 dpc for the 
highest dose and 10 dpc for the low and medium dose. However, 
since all doses gave 100% mortality (Figure 1b), the lowest dose 
(2 × 102 bacteria per fish) was chosen for Experiment 2 and the start 
of medication was set to 5 dpc.
The doses of P. atlantica gave onset of mortality at days 9, 11 
and 12 post- challenge for the high (5 × 103 bacteria per fish), me-
dium (1 × 103 bacteria per fish) and low (2 × 102 bacteria per fish), 
doses respectively. The cumulative mortality was 100% for the two 
highest doses, and 50% for the low dose (Figure 1c). It was therefore 




Total dose during 
treatment (mg/kg)
Amount of medical feed (% of 
body weight)a Days of treatment
Floraqpharma 
vet.
FFC20 2g/kg 20 200 1.0% Daily, dpc 5– 14
Floraqpharma 
vet.
FFC20 2g/kg 20 300 1.0% Daily, dpc 5– 19
Oxolinic acid vet. OA25 5g/kg 25 150 0.5% Dpc 5, 6, 8,10, 12, 14
Oxolinic acid vet. OA25 5g/kg 25 250 0.5% Daily, dpc 5– 14
aTotal amount of medical and non- medical feed was 1.5% of body weight




ml) OA (μg/ml) FLU (μg/ml)




Pasteurella atlantica 0.125 0.5 0.25
F I G U R E  2   Survival curve of lumpfish experimentally challenged 
with Vibrio anguillarum after antibacterial treatments. Black line is 
non- treated control (n = 4 tanks, 30 fish in each tank), light blue 
line is treatments with FFC 10 mg kg−1 day−1 for 10 days, dark blue 
line is treatments with FFC 20 mg kg−1 day−1 for 10 days, red line 
is treatments with OA FFC 25 mg kg−1 day−1 for 6 days, and grey 
line is treatments with FLU 25 mg kg−1 day−1 for 6 days (see Table 1 
for more details of feeding during the treatment period). Average 
of three parallel tanks (with 30 fish in each tank) is shown for all 
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decided to use a dose of 5 × 102 bacteria per fish in the main exper-
iment and to start medication 5 dpc.
3.3 | Experiment 1: Treatment of lumpfish after 
experimental challenge with V. anguillarum
Following the challenge with V. anguillarum, the mortality started 5 
dpc in the non- medicated groups (total of 120 fish, 4 tanks each with 
30 fish). The mortality rate was rapid reaching a cumulative mor-
tality of 62% at 9 dpc. At the end of the experiment (25 dpc), the 
mean cumulative mortality in the 4 control tanks was 68% (Figure 
S1) However, in one tank, the cumulative mortality was signifi-
cantly lower (43%) compared with the mean value of the remaining 
three (77.7%). Medication, started 2 dpc, was very efficient for all 
the drugs tested resulting in mean cumulative mortalities of 2.2% 
(FFC10), 1.1% (FFC20), 3.3% (OA) and 11.1% (FLU). The Kaplan– 
Meier survival analysis (Figure 2) showed a statistically significant 
effect of all treatment doses and antibacterial agents (p < .001). 
Pairwise comparison between groups showed that all the medicated 
groups were statistically significantly different from the non- treated 
control groups. No statistical difference between the medicated 
groups was found, except for between FFC20 and FLU (Table S1). 
The RPS values ranged from 84% to 98.6%, reflecting the high ef-
ficacy of all the antibacterials tested to treat vibriosis in lumpfish.
Macroscopic observation of moribund fish had swollen gut and 
ascites in the abdominal cavity (Figure 3a). Identification of V. anguil-
larum as the causative pathogen was verified by the Vibrio aggluti-
nation test and growth on Vibrio selective agar (TCBSA) (Figure 3b).
3.4 | Experiment 2: Treatment of lumpfish after 
experimental challenge with atypical A. salmonicida
Atypical A. salmonicida used for challenge was grown at 18°C since it 
may not express the A- layer surface protein at higher temperatures. 
The A- layer is important for virulence, and an SDS- PAGE was per-
formed to ensure that the A- layer was present (Figure 5a). Mortality 
in the challenged, non- medicated groups (total of 120 fish, 4 tanks 
each with 30 fish) started 10 dpc and had reached 98.3% 17 dpc. 
The medication started at 5 dpc, and high mortalities were seen in 
the groups of fish given FFC10, OA and FLU (Figure S2). In the FFC20 
groups, a lower mortality was observed until 30 dpc (14 days after 
terminated medication). However, between 30 and 40 dpc, the mor-
tality rate increased significantly, and cumulative mortality reached 
82.2% at the end of the experiment (Day 48) (Figure S2). According 
to the Kaplan– Meier survival analysis, all the treatments were sig-
nificantly different from the non- treated group (Figure 4, Table S2). 
However, the RPS values were low and ranged from 7% to 23%, in-
dicating that none of the tested antibacterials and doses efficiently 
treated atypical furunculosis infection in lumpfish.
Macroscopic observations of moribund fish were swollen gut 
(Figure 5b) and white nodules in head kidney, liver and other internal 
organs (Figure 5c,d). To investigate whether atypical A. salmonicida 
reisolated from the fish had A- layer, a single colony was streaked 
onto a blue agar plate. Blue colour verified the presence of A- layer 
(Figure 5e).
3.5 | Experiment 3: Treatment of lumpfish after 
experimental challenge with P. atlantica
Based on results in Experiment 2 (Figure 4), and the indications 
that P. atlantica might be a facultative intracellular bacterium, we 
chose to compare the treatment of FFC 20 mg kg−1 day−1 for 10 and 
15 days, and OA 25 mg kg−1 day−1 for 6 days (5, 6, 8, 10, 12 and 
14 dpc) and 10 days. Mortality in the challenged, non- medicated 
groups (total of 120 fish, 4 tanks each with 30 fish) started at 10 dpc. 
The mortality rate in the control groups was high, and cumulative 
mortality had reached 71.7% after 5 days and 76.7% at the end of 
the experiment. A low mortality rate was obtained for both medica-
tion regimens with FFC (FFC20 daily for 10 and 15 days) (Figure S3). 
However, the fish treated for 10 days were less active and had a 
darker skin pigmentation than fish treated for 15 days. For fish medi-
cated with OA, a major difference in cumulative mortality was ob-
served between the groups treated for 10 days with 22.2% mortality 
and those treated for 6 days with 54.4% mortality. Results from the 
Kaplan– Meier survival analysis are summarized in Figure 6 and Table 
S3, showing a significant effect of all the treatment regimens, and 
also statistical differences between FFC and OA. The RPS values for 
florfenicol were found to be 95.7% for the 10- day medication regi-
men and 97% when treated for 15 days. A major difference in RPS 
was found using OA where daily administration of 25 mg/kg for 10 
consecutive days (total dose 250 mg/kg) gave an RPS value of 71%, 
whereas 6 administrations over a 10- day period (total dose 150mg/
kg) were much less efficient with an RPS value of 29.1%.
F I G U R E  3   Macroscopic observations 
of diseased lumpfish with vibriosis. (a) 
Swollen anus and ascites in the abdominal 
cavity and (b) bacteria growing on agar 
plates with Vibrio selective medium 
containing thiosulphate– citrate– bile salts– 
sucrose agar(a) (b)
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Macroscopic observations of moribund fish were white spots 
around the eyes and on the skin (Figure 7a), erosion of the lower 
jaw (Figure 7b) and subcutaneous bleeding on the gill operculum 
(Figure 7c). Bacteria samples from head kidney were streaked into 
blood agar plates. Single colonies were further streaked on new 
plates. Tiny colonies characteristic of Pasteurella atlantica were ob-
served after about 4– 5 days (Figure 7d).
It is well known that diseased fish often have reduced appetite. 
This is also true for heavily infected lumpfish, but in this study, lump-
fish showed generally good appetite and feed pellets were often 
F I G U R E  4   Survival curve of lumpfish experimentally challenged 
with atypical Aeromonas salmonicida after antibacterial treatments. 
Black line is average of non- treated control (n = 4 tanks, each 
with 30 fish in each), light blue line is treatments with FFC 
10 mg kg−1 day−1 for 10 days, dark blue line is treatments with FFC 
20 mg kg−1 day−1 for 10 days, red line is treatments with OA FFC 
25 mg kg−1 day−1 for 6 days, and grey line is treatments with FLU 
25 mg kg−1 day−1 for 6 days (see Table 1 for more details of feeding 
during the treatment period). Average of three parallel tanks (with 
30 fish in each) is shown for all treatment groups. The treatment 













































F I G U R E  5   Protein profile and 
macroscopic observation after challenge 
with atypical Aeromonas salmonicida. 
(a) 12% SDS- PAGE. Lane 1: SDS- PAGE 
standard, low range molecular markers; 
Lane 2: start culture grown at 18°C; Lane 
3: main culture used for challenge grown 
at 18°C; and Lane 4: culture grown at 
20°C. Arrow indicates A- layer protein, 
(b) swollen anus, (c) white nodules in 
the head kidney, (d), white nodules on 
liver and other organs and (e) reisolated 
bacteria streaked on the right- hand side of 
a blue agar plate. A white colony (atypical 
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F I G U R E  6   Survival curve of lumpfish experimentally challenged 
with Pasteurella atlantica after antibacterial treatments. Black line 
is average of non- treated control (n = 4 tanks, with 30 fish in each 
tank), light blue line is treatments with FFC 20 mg kg−1 day−1 for 
10 days, dark blue line is treatments with FFC 20 mg kg−1 day−1 
for 15 days, red line is treatments with OA FFC 25 mg kg−1 day−1 
for 6 days, and green line is treatments with OA 25 mg kg−1 day−1 
for 10 days (see Table 2 for more details of feeding during the 
treatment period). Average of three parallel tanks (with 30 fish 
in each) is shown for all treatment groups. The treatment period 
is shaded grey. Statistical analyses are shown in Table S3. RPS 
(relative percentage survival) is given for each treatment
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found in the stomach of moribund and dead lumpfish. Oral adminis-
tration of the antibacterials is therefore considered a good alterna-
tive for lumpfish.
4  | DISCUSSION
Lumpfish are vulnerable to bacterial infections, and antibacterial 
treatment of diseased fish is needed to maintain good fish welfare. 
Although medicated feeds are commercially available for lumpfish in 
Norway, no protocols for recommended doses and treatment regi-
mens are accessible. Therefore, this study was initiated to investi-
gate the efficacy of three antibacterial agents, FFC, OA and FLU, 
to treat infections caused by V. anguillarum, atypical A. salmonicida 
and P. atlantica in lumpfish. The three antibacterials were chosen due 
to availability as medicated feed (FFC and OA) and based on phar-
macokinetic properties and increased sensitivity towards FLU com-
pared with OA of some isolates of A. salmonicida. FLU was included 
in this study as an alternative to OA.
In this study, the final cumulative mortalities in the challenged 
unmedicated groups were 69%, 99% and 77%, respectively, for 
V. anguillarum, atypical A. salmonicida and P. atlantica. These values 
are within or close to the recommended mortality range of 50% to 
90% (Amend, 1981) and 30% to 70% (Elston et al., 1995) for unmed-
icated controls suggested for dose titration trials when testing the 
efficacy of antibacterials in fish. Mortality of these magnitudes has 
previously been reported in cod when infected with V. anguillarum 
with 82% and 87.5% (Samuelsen & Bergh, 2004; Vik- Mo et al., 2005) 
and 92% when Atlantic salmon was infected with A. salmonicida 
(Samuelsen et al., 1999). This confirms the validity of the challenge 
models used in this study.
The high efficacy of the antibacterials and doses tested for the 
treatment of vibriosis in lumpfish is reflected in the high RPS values 
ranging from 84% to 98.5%. In previous investigations, these anti-
bacterials have also shown high efficacy in the treatment of vibrio-
sis in other fish species such as halibut (Samuelsen, 1997) and cod 
(Samuelsen & Berg, 2004; Vik- Mo et al., 2005). Using a similar treat-
ment regimen as in this study, the efficacy of florfenicol and oxolinic 
acid in the treatment of vibriosis in cod gave RPS values of 61% and 
68% (OA) and 64% and 77% (FFC) using doses of 10 and 20 mg/kg 
body weight d– 1, respectively (Samuelsen & Bergh, 2004), whereas 
Vik- Mo et al. (2005) found an RPS value of 72% for FLU using a daily 
dose of 25 mg/kg.
The efficacy of antibacterials to treat lumpfish infected with 
atypical A. salmonicida was examined applying the same treatment 
regimens as described for vibriosis. In this case, the RPS values 
ranged from 7% to 23%, indicating that none of the tested antibac-
terials, doses or treatment regimen efficiently treated the infection. 
It has, however, not established any guidelines that indicate when 
an RPS value is too low. This was an unforeseen result since the bac-
terial isolate used for challenge had MIC values that combined with 
pharmacokinetic values gave PK/PD indices that indicated thera-
peutic success using OA, FLU and the highest dose of FFC (Kverme 
et al., 2019; Haugland et al., 2019). Furthermore, these antibac-
terials have shown high efficacy in treating furunculosis in other 
marine species such as Atlantic salmon (Michel et al., 1980; Austin 
et al., 1983; Nordmo et al., 1998; Samuelsen et al., 1999), halibut 
(Samuelsen, 1997) and goldsinny wrasse (Samuelsen et al., 2002). 
The doses and treatment regimen used for FLU and OA in this study 
are identical to those recommended for treating furunculosis in 
Atlantic salmon. However, since the efficacy for both drugs was 
poor, further research is needed to determine potential effective 
F I G U R E  7   Macroscopic observations 
after challenge with Pasteurella atlantica. 
(a) White spots around eye and on 
the skin. (b) Erosion of the lower jaw. 
(c) Subcutaneous bleeding on the gill 
operculum. (d) Single colony of P. atlantica 
isolated from diseased fish streaked onto 
a blood agar plate
(a) (b)
(c) (d)
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doses and dosage regimens. One option may be to treat lumpfish 
with OA every day instead of days 1, 2, 4, 6, 8 and 10, as we have 
seen that OA is excreted rapidly from plasma and tissues of lump-
fish (Haugland et al., 2019), and such strategy was more efficient 
in lumpfish infected with P. atlantica (Figure 6). For treatment with 
FFC, we used the recommended procedure from the producer, as 
well as double dose (FFC20 mg/kg/day). The groups treated with 
FFC20 mg/kg/day gave lower mortality than the other groups until 
2 weeks after the antibacterial treatment, when a rapid increase 
in mortality occurred, from 31% to 77% in the next 10 days. It is 
therefore tempting to suggest that a prolonged period of medica-
tion, from 10 to 15 or 20 days, and/or a higher dose could have 
been sufficient to obtain a satisfactory survival rate. This should, 
however, be verified experimentally. One major difference between 
V. anguillarum and atypical A. salmonicida is that the latter induce 
formation of white nodules in kidney and other organs in lumpfish 
(this study and Rønneseth, Brudal, et al., 2017). Although FFC is 
efficient against intracellular microorganisms such as Piscirickettsia 
salmonis (Henriquez et al., 2016; San Martín et al., 2019), theoreti-
cally the nodule structure may reduce access of the antibacterials 
into the core of the nodule and result in concentrations of antibac-
terial agents being too low to effectively combat the bacteria. Even 
a small number of surviving bacteria can be enough to resume the 
disease. Furthermore, suboptimal concentrations may promote 
the development of bacteria resistant to antibacterial agents and 
should be avoided.
As P. atlantica has been suggested to be a facultative, intracel-
lular bacterium (Ellul, Bulla, et al., 2019), we hypothesized similar 
difficulties in combatting this disease as we experienced for atypi-
cal A. salmonicida. Thus, the dosage regimens were changed to FFC 
20 mg kg−1 day−1 successively for 10 and 15 days, and OA 25 mg/kg 
administered at days 1, 2, 4, 6, 8 and 10 and 25 mg/kg administered 
daily for 10 days. High efficacy was found for both dosage regimens 
using FFC giving RPS values of 95.7% for the 10- day medication reg-
imen and 97% when treated for 15 days. Due to the small difference 
in efficacy between the two, the suggested dosage regime is there-
fore 20 mg/kg daily for 10 days. When treating fish with antibacte-
rial agents, it is advantageous to switch between substances with 
different mechanisms of action to prevent development of resis-
tant bacteria. A major difference in RPS was found using OA where 
daily administration of 25 mg/kg for 10 consecutive days (total dose 
250 mg/kg) gave an RPS value of 71%, whereas 6 administrations 
over a 10- day period (total dose 150 mg/kg) were much less effi-
cient with an RPS value of 29.1%. Therefore, if OA is to be used as an 
alternative to FFC in treating pasteurellosis, the suggested dose and 
dosage regimen is 25 mg/kg daily for 10 days.
This study shows a good relationship between in vitro MIC and 
the efficacy of the treatment regimen for vibriosis. However, there 
was no relationship between in vitro MIC and efficacy in treating 
atypical furunculosis. This is especially evident not only for OA and 
FLU but also for the highest dose of FFC where PK/PD indices indi-
cated therapeutic success. This shows the importance of performing 
efficacy studies.
5  | CONCLUSION
The development of bacteria resistant to antibacterial agents is one 
of the most serious challenges in human and veterinary medicine 
(Giraud et al., 2006; Cabello et al., 2016; Carvalho & Santos 2016) 
and highlights the importance of developing treatment regimens 
based on knowledge.
In the current study, we found that to treat lumpfish infected 
with V. anguillarum it is possible to choose between different an-
tibacterial agents. To treat pasteurellosis, caused by P. atlantica, 
FFC20 mg/kg daily for 10 days is suitable and OA25 mg/kg daily 
for at least 10 days is an alternative to avoid using the same drug 
repeatedly. Under the condition tested in the present study, none 
of the antibacterials were efficient in treating atypical furunculosis 
in lumpfish.
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